miRNA Predictors of Pancreatic Cancer Chemotherapeutic Response: A Systematic Review and Meta-Analysis
Authors:
- Madhav Madurantakam RoyamMRMadhav Madurantakam Royam
- Rithika RameshRRRithika Ramesh
- Ritika ShankerRSRitika Shanker
- Shanthi SabarimuruganShanthi Sabarimurugan
- Chellan KumarasamyCKChellan Kumarasamy
- Nachimuthu RameshNachimuthu Ramesh
- Kodiveri Muthukalianan GothandamKodiveri Muthukalianan Gothandam
- Siddharta BaxiSBSiddharta Baxi
- Ajay GuptaAGAjay Gupta
- Sunil KrishnanSKSunil Krishnan
- Rama JayarajRama Jayaraj
Open Access
Abstract
Background: pancreatic cancer (PC) has increasing incidence and mortality in developing countries, and drug resistance is a significant hindrance to the efficacy of successful treatment. The objective of this systematic review and meta-analysis was to evaluate the association between miRNAs and response to chemotherapy in pancreatic cancer patients. Methods: the systematic review and meta-analysis was based on articles collected from a thorough search of PubMed and Science Direct databases for publications spanning from January 2008 to December 2018. The articles were screened via a set of inclusion and exclusion criteria based on the preferred reporting items for systematic review and meta-analysis (PRISMA) guidelines. Data was extracted, collated and tabulated in MS Excel for further synthesis. Hazard ratio (HR) was selected as the effect size metric to be pooled across studies for the meta-analysis, with the random effects model being applied. Subgroup analysis was also conducted, and the presence of publication bias in the selected studies was assessed. Publication bias of the included studies was quantified. Findings: of the 169 articles screened, 43 studies were included in our systematic review and 13 articles were included in the meta-analysis. Gemcitabine was observed to be the principal drug used in a majority of the studies. A total of 48 miRNAs have been studied, and 18 were observed to have possible contributions to chemoresistance, while 15 were observed to have possible contributions to chemosensitivity. 41 drug-related genetic pathways have been identified, through which the highlighted miRNA may be affecting chemosensitivity/resistance. The pooled HR value for overall survival was 1.603; (95% Confidence Interval (CI) 1.2–2.143; p-value: 0.01), with the subgroup analysis for miR-21 showing HR for resistance of 2.061; 95% CI 1.195–3.556; p-value: 0.09. Interpretation: our results highlight multiple miRNAs that have possible associations with modulation of chemotherapy response in pancreatic cancer patients. Further studies are needed to discover the molecular mechanisms underlying these associations before they can be suggested for use as biomarkers of response to chemotherapeutic interventions in pancreatic cancer.Keywords
This publication has 99 references indexed in Scilit:
- The ZEB1/miR‐200 feedback loop controls Notch signalling in cancer cellsThe EMBO Journal, 2011
- CD44‐positive cells are responsible for gemcitabine resistance in pancreatic cancer cellsInternational Journal of Cancer, 2009
- Acquisition of Epithelial-Mesenchymal Transition Phenotype of Gemcitabine-Resistant Pancreatic Cancer Cells Is Linked with Activation of the Notch Signaling PathwayCancer Research, 2009
- Profiling of 95 MicroRNAs in Pancreatic Cancer Cell Lines and Surgical Specimens by Real‐Time PCR AnalysisWorld Journal of Surgery, 2008
- Role of MicroRNA miR-27a and miR-451 in the regulation of MDR1/P-glycoprotein expression in human cancer cellsBiochemical Pharmacology, 2008
- Synergistic action of the microRNA‐17 polycistron and Myc in aggressive cancer developmentCancer Science, 2007
- Expression profiling identifies microRNA signature in pancreatic cancerInternational Journal of Cancer, 2006
- A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancerBritish Journal of Cancer, 2006
- c-Myc-regulated microRNAs modulate E2F1 expressionNature, 2005
- Quantifying heterogeneity in a meta‐analysisStatistics in Medicine, 2002